[ATRA] Atara Biotherapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 622.51 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 15.65 Change: 1.15 (7.93%)
Ext. hours: Change: 0 (0%)

chart ATRA

Refresh chart

Strongest Trends Summary For ATRA

ATRA is in the long-term up 141% in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding28.74 M EPS-3.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-4.18
P/E To EPS Growth P/S P/BV3.75 Price/Cash Per Share3.73
Price/Free Cash Flow-37.33 ROA-17.74% ROE-18.13% ROI
Current Ratio48.29 Quick Ratio Long Term Debt/Equity Debt Ratio0.02
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities69.49 M Cash From Investing Activities-13.43 M Cash From Operating Activities-6.62 M Gross Profit
Net Profit-9.16 M Operating Profit-9.31 M Total Assets169.82 M Total Current Assets169.69 M
Total Current Liabilities3.51 M Total Debt Total Liabilities3.72 M Total Revenue
Technical Data
High 52 week48.35 Low 52 week13.6 Last close41.74 Last change8.19%
RSI65.77 Average true range1.65 Beta1.87 Volume116.19 K
Simple moving average 20 days8.73% Simple moving average 50 days13.99% Simple moving average 200 days9.17%
Performance Data
Performance Week3.19% Performance Month19.98% Performance Quart17.45% Performance Half9.91%
Performance Year183.95% Performance Year-to-date20.15% Volatility daily2.77% Volatility weekly6.19%
Volatility monthly12.69% Volatility yearly43.94% Relative Volume166.51% Average Volume491.51 K
New High New Low

News

2019-03-08 13:55:07 | The Atara Biotherapeutics NASDAQ:ATRA Share Price Has Gained 122%, So Why Not Pay It Some Attention?

2019-03-07 09:00:00 | Atara Biotherapeutics to Participate in Upcoming Conferences

2019-03-06 17:20:40 | How attacking a virus in cancer patients helped a Peninsula company target MS

2019-02-27 17:20:00 | Atara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research AACR Annual Meeting 2019

2019-02-26 07:30:00 | Atara Biotherapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress

2019-02-13 08:00:00 | Consolidated Research: 2019 Summary Expectations for T-Mobile US, WestRock, Shake Shack, Atara Biotherapeutics, CorVel, and Transdigm Group — Fundamental Analysis, Key Performance Indications

2019-01-08 12:50:13 | At biotech's big event, a chance for execs to shape LGBTQ diversity on boards

2019-01-04 16:05:00 | Atara Biotherapeutics to Participate in the 37th Annual J.P. Morgan Healthcare Conference

2019-01-04 10:01:03 | Company News For Jan 4, 2019

2019-01-03 16:32:00 | Why Delta Air Lines, Atara Biotherapeutics, and Skyworks Solutions Slumped Today

2019-01-03 07:40:00 | Atara Biotherapeutics Announces Planned Chief Executive Officer Transition

2019-01-03 07:30:00 | Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy for Solid Tumors

2018-12-21 23:23:46 | Should You Avoid Atara Biotherapeutics Inc ATRA?

2018-12-15 08:00:00 | Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma EBV+ LMS

2018-12-03 20:45:00 | Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology ASH Annual Meeting

2018-11-29 14:50:00 | Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline

2018-11-27 08:30:00 | Atara Biotherapeutics to Host CAR T Breakfast Teach-In on November 29, 2018

2018-11-19 08:30:00 | Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus EBV-Specific T-Cell Immunotherapy

2018-11-06 08:11:19 | Atara Biotherapeutics: 3Q Earnings Snapshot

2018-11-06 07:30:00 | Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress

2018-11-01 09:03:00 | Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology ASH Annual Meeting and European Society for Medical

2018-10-16 07:40:00 | Report: Exploring Fundamental Drivers Behind Monroe Capital, Anavex Life Sciences, Haynes International, Atara Biotherapeutics, Lands' End, and Envestnet — New Horizons, Emerging Trends, and Upcoming Developments

2018-09-26 08:41:12 | Atara Biotherapeutics ATRA in Focus: Stock Moves 6.9% Higher

2018-09-24 16:55:00 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-09-11 08:00:00 | Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors

2018-09-06 07:30:00 | Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies

2018-08-31 08:00:00 | Atara Biotherapeutics to Participate at Two Upcoming Conferences

2018-08-16 07:40:00 | Analysis: Positioning to Benefit within Quanex Building Products, Molecular Templates, Atara Biotherapeutics, Forward Industries, Apollo Endosurgery, and Myomo — Research Highlights Growth, Revenue, and Consolidated Results

2018-08-06 16:50:00 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-08-01 08:12:36 | Atara Biotherapeutics: 2Q Earnings Snapshot

2018-08-01 08:00:00 | Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress

2018-07-31 16:45:00 | Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference

2018-07-12 07:15:00 | Free Pre-Market Technical Recap on ArQule and Three Additional Biotech

2018-06-25 08:00:00 | Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline

2018-06-20 11:30:00 | 2 High-Flying Biotech Stocks With Even More Room to Grow

2018-06-20 06:01:00 | 3 Small-Cap Biotech Stocks to Keep on Your Radar

2018-06-18 09:42:34 | Why this Peninsula cell therapy company joined biotech's 'unprecedented' manufacturing boom

2018-06-15 02:30:00 | Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas

2018-06-13 08:00:00 | Atara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus EBV Infection and Multiple Sclerosis MS

2018-06-13 07:05:00 | Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities

2018-06-07 17:20:00 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-06-07 08:00:00 | Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer

2018-06-03 09:02:00 | 3 Top Growth Stocks to Buy Right Now

2018-05-29 16:05:00 | Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

2018-05-29 07:35:00 | New Research Coverage Highlights Seaboard, The Hanover Insurance Group, Atara Biotherapeutics, Plexus, NV5 Global, and Analogic — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-05-17 09:00:00 | Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association

2018-05-10 07:30:00 | Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies

2018-05-08 07:28:27 | Atara Biotherapeutics: 1Q Earnings Snapshot

2018-05-08 07:05:00 | Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress

2018-05-08 07:00:00 | Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies in Oncology, Autoimmune and Other Diseases